See All Slides - tctmd.com

Slides

Presentation TCT 2013

Use Of 4 French Systems For Treating Fem-Pop Lesions: Advantages And Disadvantages: Lessons From The 4EVER Trial Using Astron Pulsar Stents And No Closure Devices

Presenter: Koen Keirse

October 29, 2013

Presentation TCT 2013

TAVI Karlsruhe (TAVIK) – a comparison of minimal invasive and surgical aortic valve replacement in patients with severe symptomatic aortic stenosis and intermediate risk for conventional surgery

Presenter: Gerhard Schymik

October 29, 2013

Presentation TCT 2013

SORT-OUT VI: A Prospective, Randomized, All-Comers Trial of Biodegradable Polymer-Coated Biolimus-Eluting Stents vs. Biocompatible Polymer-Coated Zotarolimus-Eluting Coronary...

Presenter: Bent Raungaard

October 29, 2013

Presentation TCT 2013

How Do I Assess an Intermediate Lesion?

Presenter: William Fearon

October 29, 2013

Presentation TCT 2013

Case 2: Chronic Total Occulsion (Piedmont Heart Institute, Atlanta, GA)

Presenter: Julie Logan

October 29, 2013

Presentation TCT 2013

Long-term Safety of Everolimus-Eluting Bioresorbable Vascular Scaffold versus Cobalt-Chromium XIENCE V Stent in a Porcine Coronary Artery Model

Presenter: Fumiyuki Otsuka

October 29, 2013

Presentation TCT 2013

Repair vs. Replacement for Functional MR

Presenter: Robert Guyton

October 29, 2013

Presentation TCT 2013

TCT-9. Racial Disparity With On-Treatment Platelet Reactivity In Patients Undergoing Percutaneous Coronary Intervention

Presenter: Iakshmana Pendyala

October 29, 2013

Presentation TCT 2013

Case #1: Management of Residual Thrombus After Intracoronary Administration of Abciximab and Manual Thromboaspiration in STEMI.

Presenter: Alejandro Fernandez

October 29, 2013

Presentation TCT 2013

Prognostic impact of chronic total occlusion in ischemic heart disease and different age categories - A report from the Swedish Coronary Angiography and Angioplasty Registry

Presenter: Loes Hoebers

October 29, 2013

Advertisement

Slides

Use Of 4 French Systems For Treating Fem-Pop Lesions: Advantages And Disadvantages: Lessons From The 4EVER Trial Using Astron Pulsar Stents And No Closure Devices

TAVI Karlsruhe (TAVIK) – a comparison of minimal invasive and surgical aortic valve replacement in patients with severe symptomatic aortic stenosis and intermediate risk for conventional surgery

SORT-OUT VI: A Prospective, Randomized, All-Comers Trial of Biodegradable Polymer-Coated Biolimus-Eluting Stents vs. Biocompatible Polymer-Coated Zotarolimus-Eluting Coronary...

How Do I Assess an Intermediate Lesion?

Case 2: Chronic Total Occulsion (Piedmont Heart Institute, Atlanta, GA)

Long-term Safety of Everolimus-Eluting Bioresorbable Vascular Scaffold versus Cobalt-Chromium XIENCE V Stent in a Porcine Coronary Artery Model

Repair vs. Replacement for Functional MR

TCT-9. Racial Disparity With On-Treatment Platelet Reactivity In Patients Undergoing Percutaneous Coronary Intervention

Case #1: Management of Residual Thrombus After Intracoronary Administration of Abciximab and Manual Thromboaspiration in STEMI.

Prognostic impact of chronic total occlusion in ischemic heart disease and different age categories - A report from the Swedish Coronary Angiography and Angioplasty Registry

Search Slides

Advertisement

Advertisement

Slides

Search Slides

Sign Up for Our Newsletter

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content